Most Read Articles
Roshini Claire Anthony, 5 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 6 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
4 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.

Ledipasvir–sofosbuvir combination effective, safe in chronic hepatitis C genotype 1 infection

18 Oct 2018

Combination therapy with the NS5A inhibitor ledipasvir and NS5B inhibitor sofosbuvir (LDV/SOF) appears to be highly effective in the management of chronic hepatitis C virus (HCV) genotype 1 (GT1) infection, yielding a sustained virologic response (SVR) of >90 percent without increasing the incidence of serious adverse events, according to data from a real-world Japanese cohort.

Researchers reviewed the medical data of 1,461 GT1-infected patients (mean age, 69 years; cirrhosis, 23.8 percent; history of treatment for hepatocellular carcinoma [HCC], 10.9 percent), treated with LDV/SOF for 12 weeks. Evaluations included the rate of SVR at 12 weeks post-treatment (SVR12), incidence of adverse events and serum markers of HCC.

The overall SVR12 rate was 98.4 percent. Risk factors for treatment failure were cirrhosis (odds ratio, 4.19; p=0.014) and resistance-associated substitutions (RASs) in NS5A at baseline (odds ratio, 7.78; p=0.0004).

The SVR12 rates were 93.0 percent among patients with cirrhosis and NS5A RASs and 100 percent among those without cirrhosis or NS5A RASs.

In the group of patients who achieved SVR, reductions from baseline to end of treatment were observed in the levels of alpha-fetoprotein (AFP; from 13.4 to 6.0 ng/mL; p<0.0001), AFP-L3 (from 2.2 percent to 1.5 percent; p<0.005) and Mac-2 binding protein glycosylation isomer (M2BPGi; from 3.6 to 2.0 cutoff index; p<0.0001).

Adverse events occurred rarely and independent of age. Furthermore, there were no reductions observed in estimated glomerular filtration rate in patients with baseline chronic kidney disease stage 3.

Researchers noted that while the study specifically focused on SVR12 and did not analyse long-term prognosis including HCC occurrence, the finding of reduced M2BPGi in patients who achieved SVR suggests that viral eradication by LDV/ SOF therapy has the potential to reduce HCC risk.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 5 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 6 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
4 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.